
SignPath Pharma Announces ASCO 2025 Abstract Featuring LipoCurc for Glioblastoma
Phase I/II study of LipoCurc™ in glioblastoma accepted for poster presentation at ASCO 2025, in collaboration with Johns Hopkins. SANDY, UT, UNITED STATES, May 5, 2025 /EINPresswire.com/ -- SignPath Pharma, Inc., a Delaware-incorporated …